LENZ Therapeutics, Inc. LENZ 深 沪
交易中 05-13 10:26:09 美东时间
7.865
-0.045
-0.57%
华盛通- 最 高7.95
- 今 开7.92
- 成交量 16.86万股
- 最 低 7.50
- 昨 收 7.91
- 总市值 2.47亿
- 52周最高 50.40
- 市盈率 静 --
- 换手率 0.54%
- 52周最低 6.83
- 委 比 1.48%
- 总股本 3135.44万
- 历史最高 230.79
- 量 比 1.48
- 振 幅 5.69%
- 历史最低 3.92
- 每 手 1
- 风险率 11.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
今天 11:46
Piper Sandler Downgrades LENZ Therapeutics to Neutral, Lowers Price Target to $12
Piper Sandler analyst Biren Amin downgrades LENZ Therapeutics (NASDAQ:LENZ) from Overweight to Neutral and lowers the price target from $39 to $12.
05-12 18:23
LENZ Therapeutics Q1 EPS $(1.32) Misses $(1.05) Estimate, Sales $1.901M Beat $1.759M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.05) by 25.71 percent. This is a 149.06 percent decrease over losses of $(0.53) per share
05-12 04:07
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
美股大行评级 | 瑞银大幅上调西部数据、希捷科技目标价！汇丰银行上调英特尔评级至"买入"，目标价从50美元升至95美元
今日重点评级关注：HC Wainwright & Co.：维持Century Therapeutics"买入"评级，目标价从2美元升至5美元；Oppenheimer：维持Climb Bio"跑赢大市"评级，目标价从10美元升至18美元
04-22 12:41
LENZ Therapeutics Files Marketing Authorization Application Review, Approval Of VIZZ To Medicines And Healthcare products Regulatory Agency To Treat Presbyopia In Adults
LENZ Therapeutics, Inc. (NASDAQ:LENZ) today announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for the review
04-20 20:04
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $26
Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $52 to $26.
03-26 23:42
美股大行评级 | 最高240美元，潜在涨幅53%！ARM获多家大行上调目标价；Braze 评级上演 “两极反转”，小摩、巴克莱上调，高盛、花旗下调
今日重点评级关注：HC Wainwright & Co.：维持OCUGEN"买入"评级，目标价从7美元升至10美元；HC Wainwright & Co.：维持Maze Therapeutics"买入"评级，目标价从60美元升至110美元
03-26 11:41
LENZ Therapeutics Q4 EPS $(1.16) Misses $(0.96) Estimate, Sales $1.588M Miss $1.886M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.96) by 20.83 percent. This is a 152.17 percent decrease over losses of $(0.46) per share
03-24 20:01
